

1 **Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized**
2 **Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia**
3 **Syndrome (The COVIVA Study)**

4 David Saunders^{1§}; Thomas B. Arnold^{1,2,4}; Jason M. Lavender^{1,2,4}; Daoqin Bi^{1,4,5}; Karl Alcover¹;
5 Lydia D. Hellwig^{1,3,5}; Sahar T Leazer^{1,2,4}; Roshila Mohammed^{1,2,4}; Bethelhem Markos^{1,2,4};
6 Kanchana Perera^{1,2,4}; Dutchabong Shaw^{1,5}; Priscilla Kobi^{1,5}; Martin Evans⁶; Autumn Mains^{1,2,4};
7 Marian Tanofsky-Kraff^{1,4}; Emilie Goguet^{1,5}; Edward Mitre¹; Kathleen P Pratt¹; Clifton L
8 Dalgard^{1,3}; Mark C Haigney, MD^{1,4}

9 **§ - Corresponding Author**

10 COL David Saunders, MD, MPH
11 Uniformed Services University
12 4301 Jones Bridge Road
13 Bethesda, MD 20814-4712
14 Office: (301) 318-6024
15 Email: david.saunders@usuhs.edu
16

17 **Affiliations**

18 1 – Uniformed Services University School of Medicine, Bethesda, Maryland
19 2 - The Metis Foundation, San Antonio, Texas
20 3 - Center for Military Precision Health, Uniformed Services University, Bethesda, MD
21 4 - Military Cardiovascular Outcomes Research, Uniformed Services University, Bethesda, MD
22 5 - Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
23 6 – Walter Reed Army Institute of Research, Silver Spring, MD
24
25

26 **Abstract**

27 **Background:** Significant clinical similarities have been observed between the recently
28 described ‘Long-Haul’ COVID-19 (LHC) syndrome, Postural Orthostatic Tachycardia
29 Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST). Shared symptoms include light-
30 headedness, palpitations, tremulousness, generalized weakness, blurred vision, chest pain,
31 dyspnea, “brain-fog”, and fatigue. Ivabradine is a selective sinoatrial node blocker FDA-
32 approved for management of tachycardia associated with stable angina and heart failure not fully
33 managed by beta blockers. In our study we aim to identify risk factors underlying LHC, as well
34 as the effectiveness of ivabradine in controlling heart rate dysregulations and POTS/IST related
35 symptoms.

36 **Methods/Design:** A detailed prospective phenotypic evaluation combined with multi-omic
37 analysis of 200 LHC volunteers will be conducted to identify risk factors for autonomic
38 dysfunction. A comparator group of 50 volunteers with documented COVID-19 but without
39 LHC will be enrolled to better understand the risk factors for LHC and autonomic dysfunction.
40 Those in the cohort who meet diagnostic criteria for POTS or IST will be included in a nested
41 prospective, randomized, placebo-controlled trial to assess the impact of ivabradine on
42 symptoms and heart rate, assessed non-invasively based on physiologic response and ambulatory
43 electrocardiogram. Additionally, studies on catecholamine production, mast cell and basophil
44 degranulation, inflammatory biomarkers, and indicators of metabolic dysfunction will be
45 measured to potentially provide molecular classification and mechanistic insights.

46 **Discussion:** Optimal therapies for dysautonomia, particularly associated with LHC, have yet to
47 be defined. In the present study, ivabradine, one of numerous proposed interventions, will be

48 systematically evaluated for therapeutic potential in LHC-associated POTS and IST.
49 Additionally, this study will further refine the characteristics of the LHC-associated POTS/IST
50 phenotype, genotype and transcriptional profile, including immunologic and multi-omic analysis
51 of persistent immune activation and dysregulation. The study will also explore and identify
52 potential endotheliopathy and abnormalities of the clotting cascade.

53

54 **Trial registration:** ClinicalTrials.gov, ID:NCT05481177 Registered on 29 July 2022.

55

56 **Keywords:** Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-CoV-2 or COVID-19);
57 long-haul COVID-19 (LHC); postural orthostatic tachycardia syndrome (POTS); ivabradine
58 (Procoralan); clinical trial

59 **Background**

60 **Introduction & Significance**

61 Between 13-70% of coronavirus disease 2019 (COVID-19) survivors continue to experience
62 symptoms after >12 weeks of resolution of primary illness. This phenomenon has been termed
63 “Long Haul COVID-19” (LHC). There is a plethora of reported LHC symptoms including
64 dizziness, tachycardia, palpitations, confusion, fatigue, memory loss, dyspnea and many more
65 (1).ⁱ LHC symptoms greatly degrade an individual’s quality of life and functional ability. The
66 Postural Orthostatic Tachycardia Syndrome (POTS) sometimes referred to as Soldier’s Heart or
67 DaCosta’s Syndrome is a particularly debilitating condition (2). POTS overlaps with several of
68 the clinical features of LHC, particularly tachycardia, confusion, and fatigue. Prior to COVID-
69 19, POTS was a relatively rare phenomenon, affecting otherwise healthy individuals following
70 viral illness or trauma. Recent reports suggest that a substantial number of LHC patients meet
71 diagnostic criteria for POTS (3). Clinics dedicated to the treatment of autonomic disorders are
72 seeing substantially increased numbers of POTS patients among those who have recovered from
73 COVID-19. The American Autonomic Society issued a statement alerting clinicians to consider
74 the possibility of POTS when assessing LHC patients (4). However, the actual prevalence of
75 those with LHC also meeting the diagnostic criteria for POTS has been only minimally
76 characterized. Inappropriate Sinus Tachycardia (IST) is a related syndrome associated with sinus
77 heart rates that are elevated above 100 beats per minute at rest and an average rate >90 over a 24-
78 hour period. The symptoms associated with IST are similar to those of POTS.

79 The symptoms of LHC have been described in prospective studies. In a prospective study of 312
80 individuals diagnosed with COVID during the first pandemic wave in Norway, 55% reported
81 symptoms 6 months following primary infection. The most common symptoms were fatigue

82 (30%), disturbed taste and/or smell (27%), concentration (19%) or memory (18%) problems,
83 dyspnea (15%), headache (11%), and palpitations (6%) (5). These symptoms are similar to those
84 reported by POTS sufferers, which include light-headedness, palpitations, tremulousness,
85 generalized weakness, blurred vision, chest pain, dyspnea, “brain-fog”, and fatigue (6). Limited
86 systematic data exist regarding the hemodynamic, autonomic, or metabolic phenotypes in LHC,
87 or corresponding genotypic risk factors.

88 Consensus diagnostic criteria for POTS has been endorsed by numerous professional societies
89 (7). These criteria include chronic symptoms and a defined sustained increase in heart rate after
90 standing or head-up tilt. This heart rate increase should not be attributable to orthostatic
91 hypotension or other conditions that may provoke sinus tachycardia. Additionally, the
92 demonstrated increase in heart rate must coincide with the symptoms in question (such as light-
93 headedness, palpitations, tremulousness, generalized weakness, blurred vision, and fatigue,
94 vasovagal syncope). Additionally, consensus statements define diagnostic criteria for IST as the
95 presence of both average and absolute elevated resting sinus heart rate (8).

96 The present study will aim to further define risk factors for LHC and POTS/IST, better
97 understand the underlying pathophysiology, estimate the proportion of individuals presenting
98 with POTS symptoms who have the diagnosis, and evaluate an intervention (ivabradine) in a
99 nested, randomized trial in those found to have POTS.

100 **Evidence for LHC/POTS and Immunologic Dysregulation**

101 While increasingly common, the pathophysiological mechanisms driving post-COVID-19
102 cardiovascular and autonomic complications, including tachycardia, remain unknown (9).
103 Nalbandian *et al* suggest that possible mechanistic pathways responsible for LHC include 1)

104 residual damage of cells and tissues caused directly by the SARS-CoV-2 infection, 2) expected
105 long-term damage due to critical illness, and 3) persistent immunological aberrations (10).
106 Several mechanisms have been postulated by which immune dysfunction may contribute to
107 LHC. First, sustained inflammation, triggered by persistent virus, viral antigens, or immune
108 dysregulation triggered by the initial infection, could directly cause cardiac damage (11).
109 Persistent immune activation can lead to cardiac fibrosis, and prolonged exposure to pro-
110 inflammatory cytokines can prolong ventricular action potentials (12). Significantly for this
111 study, chronic inflammation can also affect autonomic pathways (10). Second, individuals with
112 LHC may develop T-cell and/or natural killer (NK) cell exhaustion, defined as reduced cellular
113 responses to SARS-CoV-2, and this can then lead to viral persistence and the symptoms of LHC.
114 Finally, COVID-19 may trigger development of autoantibodies, including antiphospholipid
115 antibodies or antibodies against adrenergic and muscarinic receptors, that could then contribute
116 to the cardiovascular manifestations of LHC (11, 13). Immunologic mechanisms discussed in the
117 literature include persistent immune activation, T-cell/NK cell exhaustion, and development of
118 autoantibodies (10-14). The study will investigate whether other immune mechanisms play a role
119 in contributing to post-COVID-19 POTS. Alterations in basophil and mast cell responsiveness
120 may influence development of POTS syndrome. One of the possible mechanisms underlying
121 POTS is activation of basophils and mast cells by parasympathetic neurons. This hypothesis is
122 supported by a recent study where two thirds of individuals with POTS demonstrated increased
123 histamine or other mast cell mediators in the blood in the setting of postural tachycardia (15).
124 The present study will investigate whether this also occurs in post COVID-19 POTS.
125 Biomarkers of mast cell and basophil degranulation, including histamine, tryptase, and
126 prostaglandin D2, will be measured before and after orthostasis testing. Additionally, participants

127 will be evaluated for increased basophil sensitivity to activation by calcitonin gene-related
128 peptide (CGRP) and substance P at baseline - molecules released by parasympathetic nerves that
129 can stimulate mast cell and basophil activation. Immune complexes may be important drivers of
130 persistent inflammation after resolution of SARS-CoV-2 infection. Immune complexes are
131 known to develop in the context of SARS-CoV-2 infection, and it has been demonstrated they
132 are able to persist in tissues and drive inflammation despite the resolution of viral infection (16,
133 17). Such immune complexes can interact with the mast cell via Fc γ -receptor. These complexes
134 interact with a host of other immunological systems and affect NK cell activity. NK cell
135 responsiveness to immune complexes may be measured as well if indicated.

136 **Evidence for LHC/POTS and Hematologic Dysfunction**

137 In addition to immunologic dysregulation and cytokine storm, blood coagulation and
138 anticoagulant pathways, as well as fibrinolysis, are perturbed in COVID-19, increasing risks of
139 both macro/ micro-thrombosis and hemorrhagic pathologies with increasing infection severity
140 (18). Plasma or serum levels of fibrin D-dimer, a product of fibrinolysis, are now routinely
141 measured in clinical assays for COVID-19 patients, while assays for additional up- or down-
142 regulated pro- and anti-coagulant proteins and their activities are still largely restricted to
143 research laboratories. For example, the acute-phase protein von Willebrand factor (VWF) is
144 highly up-regulated in severe COVID-19, concomitant with reduced activity of the protease
145 ADAMTS13, which cleaves VWF following its secretion from endothelial cells or platelets,
146 thereby reducing its prothrombotic potential (19, 20). Persistent endothelial damage is a feature
147 of LHC (21). Emerging evidence indicates that endotheliopathy and a prothrombotic phenotype
148 also persist in LHC (22). This includes altered thrombin lag times, endogenous potential and
149 peak levels, as well as up-regulated VWF, factor VIII (FVIII) and thrombomodulin (23).

150 A recently published preprint reported that gamma prime fibrinogen (GPF), which is translated
151 from a splice variant of fibrinogen, is highly up-regulated in severe COVID-19 (22).
152 Interestingly, GPF binds to the heparin-binding exosite on thrombin, preventing its neutralization
153 by heparin and antithrombin III and increasing resistance of clots to fibrinolysis (24). It is
154 hypothesized that GPF, like VWF and FVIII, may also be up-regulated in LHC. Further
155 characterizing altered hemostatic profiles in LHC could suggest more effective measures to
156 prevent thrombosis, e.g., potential effectiveness of direct thrombin inhibitors in patients with
157 elevated GPF and/or who have failed low-molecular weight heparin therapy.

158 **Psychosocial, Quality of Life, and Cognitive Factors**

159 Despite a growing number of studies documenting the clinical impact of LHC, few have directly
160 examined the broad psychosocial and cognitive functioning impairments that may affect
161 individuals who suffer from the condition (25). COVID-19, in the absence of the long-haul
162 syndrome, has been associated with numerous psychological symptoms including, but not
163 limited to psychological distress, post-traumatic stress disorder, secondary traumatic stress,
164 complicated grief, and anxiety (26-29). Not surprisingly, symptoms reported in the association
165 with LHC are remarkably similar to many of the criteria for mood and anxiety disorders
166 described in the Diagnostic and Statistical Manual of the DSM, 5th edition (DSM-5) (30). For
167 example, heart palpitations, cognitive impairment, headache, sleep disturbance, dizziness,
168 delirium, reduced appetite, and fatigue are also often present in several DSM-5 disorders. To
169 date, preliminary research on adults with LHC suggests that depression/anxiety, cognitive
170 impairment, loss of concentration, fatigue, and insomnia are common (31, 32). Importantly, this
171 research has also found that participants reported a significantly diminished quality of life. While
172 there are clearly physiological underpinnings of COVID-19 contributing to symptoms during

173 acute illness, given the links between psychological functioning and COVID-19 that resolves, the
174 extent to which LHC is related to psychosocial and cognitive functioning warrants further
175 exploration.

176 **Genetic and Phenotypic Assessments**

177 Preliminary work has elucidated genetic mechanisms responsible for COVID-19
178 pathophysiology. The involvement of the cell surface receptor angiotensin converting enzyme 2
179 (ACE2) and the transmembrane protease serine-2 (TMPRSS2) protein in binding and cleavage of
180 SARS-CoV-2 has been reported in multiple studies (33). The association between the
181 polymorphisms of renin-angiotensin-aldosterone system-related genes, i.e., ACE2 and
182 TMPRSS2, and the severity of COVID-19 disease have been thoroughly investigated (34).
183 Studies have correlated single nucleotide polymorphisms (SNPs) of ACE2 and TMPRSS2 with
184 lower severity of COVID-19 in an Indian population (35, 36), and a lower risk of developing
185 severe COVID-19 (37). Another meta-analysis found that a TMPRSS2 SNP was not associated
186 with more severe COVID-19 manifestations, whereas two ACE2 SNPs were associated with
187 more severe COVID-19 manifestations by genotype but not allele (38).

188 A recent study identified that the ACE2 T allele was associated with a higher risk for critical COVID-19 c
189 ACE2 with a higher risk of severe COVID-19 (41). Given ACE2 and TMPRSS2 polymorphism
190 associations with severe COVID-19, the study will investigate associations with post-COVID
191 symptoms including fatigue and dyspnea. These polymorphisms influence variability of ACE2
192 and TMPRSS2 expression with the ACE2 rs2285666 polymorphism elevating ACE2 expression
193 up to 50%. Higher expression of ACE2 can trigger vascular constriction, worsening endothelial
194 dysfunction, fibrosis and inflammation (42, 43).

195 Reports have noted elevated plasma ACE2 activity three months after the acute infection in
196 individuals with long-COVID as compared to uninfected matched controls (44). Long-lasting
197 systematic inflammation after acute SARS-CoV-2 is associated with more severe post-COVID
198 symptoms (45). These associations could underlie post-COVID symptoms (44). It is plausible
199 that intron/missense variants of ACE2 and TMPRSS2 polymorphisms could be associated with
200 LHC development.

201 Most studies investigating the role ACE2 or TMPRSS2 SNPs have focused on the risk of being
202 infected or the severity of COVID-19 disease in the acute phase. Two recent studies investigated
203 the association between five COVID-19 associated SNPs in AC1, ACE2 and TMPRSS2 and
204 long term post-COVID symptoms in previously hospitalized COVID-19 survivors (46, 47).
205 However, the SNPs assessed, although previously associated with COVID-19 severity, did not
206 predispose for developing LHC symptoms in people who were previously hospitalized due to
207 COVID-19. To date, data on genomic associations and predispositions with the development of
208 LHC remain limited. Strong correlation between disease severity and predisposition to LHC
209 have not been established. Genetic susceptibility to endophenotypes overlapping with LHC may
210 contribute to the condition spectrum. The study aims to evaluate polygenic risk factors across
211 medical phenotypes, including cardiovascular, hematologic, immunologic and neurological
212 conditions, for enrichment in POTS/IST subjects from whole genome sequencing and multi-omic
213 signature analysis. Multi-omic profiling aims to enable molecular classification of POTS/IST
214 subgroups from transcriptome and proteome expression of key host and disease factors.

215 **Management of POTS**

216 Postural Orthostatic Tachycardia Syndrome (POTS) occurs frequently in patients with LHC.
217 There is currently no agreed upon standard of care for POTS. Rate control medications have
218 been studied, as have exercise training and other medications. Low-dose propranolol was
219 previously recommended based on a trial performed at Vanderbilt. A subsequent study by a
220 different group, however, found no improvement in quality of life when using propranolol (48).
221 Propranolol, the recommended agent, is associated with penetration of the central nervous
222 system resulting in nightmares and depression. Bronchospasm is a common (and sometimes life-
223 threatening) complication.

224 In a recent review of POTS (2020), the Canadian Cardiovascular Society acknowledged that case
225 series of ivabradine in POTS have been reported to have 68-78% effectiveness with respect to
226 controlling heart rate and symptoms (49). Ivabradine is a selective sinoatrial node blocker FDA-
227 approved for management of tachycardia associated with stable angina and heart failure not fully
228 managed by beta blockers. It blocks the hyperpolarization-activated cyclic nucleotide-gated
229 (HCN) channel responsible for the cardiac pacemaker I_{funny} current, which regulates heart rate. In
230 clinical electrophysiology studies, cardiac effects were most pronounced at the sinoatrial (SA)
231 node, with lesser prolongation of the AH and PR intervals. There was no effect on ventricular
232 repolarization or myocardial contractility. Ivabradine causes a dose-dependent reduction in heart
233 rate in proportion to the baseline heart rate. Ivabradine's relative lack of effect on the respiratory
234 system may avoid exacerbating dyspnea experienced by LHC patients. This has been confirmed
235 in a small RCT of patients with postural orthostatic tachycardia syndrome (POTS) where it was
236 shown to safely reduce heart rate (50). Other treatments, including salt supplementation,
237 midodrine, and fludricortisone may soon be superseded by this novel therapy. IST is a similarly

238 intractable clinical condition that is believed to be responsive to ivabradine, although the drug
239 does not have FDA approval for that indication.

240

241 **Methods/Design**

242 **Aims and Objectives**

243 This prospective study of 200 LHC volunteers with a nested RCT will assess the effect of
244 ivabradine on heart rate and symptoms in those meeting diagnostic criteria for POTS or IST. A
245 comparator group of 50 volunteers with documented COVID-19 but without LHC will help
246 identify the risk factors for LHC and autonomic dysfunction. The comparator group will also be
247 evaluated for POTS and eligible for inclusion in the nested RCT.

248 The primary aim is to identify the proportion of volunteers with relevant symptoms diagnosed
249 with postural orthostatic tachycardia syndrome (POTS) or inappropriate sinus tachycardia (IST).

250 We will first attempt to address the frequency of clinically confirmed POTS in those with
251 persistent COVID-19 symptoms suggestive of autonomic dysfunction. The second aim is to
252 determine the potential benefits of ivabradine treatment for those with LHC-associated POTS or
253 IST. A nested clinical trial for Ivabradine responsiveness on reduction of tachycardia.
254 Ivabradine is a drug approved to treat tachycardia in severe heart failure with some demonstrated
255 improvement in POTS outcomes.ⁱⁱ Those with confirmed POTS or IST will be randomized to
256 ivabradine or placebo to determine efficacy in reducing heart rate and POTS symptoms.

257 The third aim is to characterize potential differences in hematologic, metabolic, immunologic,
258 and genetic variants among volunteers with and without LHC. Cellular and molecular
259 characterization of LHC and non-LHC participants will be performed. This aim will identify

260 risk factors and provide mechanistic insights into the pathophysiology of LHC and POTS for
261 those with and without LHC. The biopsychosocial mechanisms of LHC and POTS will also be
262 explored. Study objectives are summarized in Table 1.

263 **Ethical Approval**

264 The study was approved by the Uniformed Services University of the Health Sciences
265 Institutional Review Board in June 2022 and registered with clinicaltrials.gov as NCT05481177.
266 The study will adhere to the principles of Good Clinical Practice.

267 **Study design**

268 The study design is shown in Figure 1. The study will enroll a cohort of 200 volunteers with
269 LHC from both the Military Health System (MHS) and civilian populations in the Washington
270 metropolitan area (which includes the District of Columbia and parts of Maryland, Virginia, and
271 West Virginia). In addition, a small comparator group of 50 volunteers with a confirmed
272 COVID-19 diagnosis but without ongoing sequelae will be enrolled in the overall cohort.

273 **Study Site and Population**

274 The study will take place at a single center in suburban Maryland. The cohort will be enriched
275 for volunteers with one or more signs or symptoms consistent with autonomic dysfunction
276 indicating potential POTS/IST during the recruiting process. Examples include dizziness, heart
277 palpitations, fainting spells or racing heart rate. Other non-specific symptoms associated with
278 POTS have included headache, ‘brain fog’ or confusion, gastrointestinal disturbances, and
279 fatigue. Inclusion criteria are: 18-80 years old; History of documented COVID-19 infection of
280 any severity to include a positive COVID-19 PCR, or antibody test; meet criteria for ‘long-haul’
281 COVID-19 with persistent symptoms >12 weeks following acute illness for the LHC cohort (or
282 without persistent long-haul COVID-19 symptoms for the non-LHC cohort); able and willing to
283 provide informed consent and participate for the 1-year study duration; Willing to participate in
284 the nested Ivabradine RCT if enrollment criteria are met; and access to healthcare and health
285 insurance.

286 Exclusion criteria are resting heart rate <60 bpm; atrial fibrillation; supraventricular tachycardia;
287 allergic reaction or known contraindications to study drug; pregnant/lactating females; impaired
288 gastrointestinal drug absorption; acute suicidality identified at screening; taking any of the
289 following unless discontinued in consultation with the volunteer’s healthcare provider and a one-
290 week washout period: beta-blockers, calcium-channel blockers, cholinesterase inhibitors
291 (pyridostigmine), vasoconstrictors (midodrine, octreotide, droxidopa, stimulants), sympatholytics
292 (clonidine, methyldopa), blood volume enhancers (fludrocortisone, desmopressin, salt
293 supplementation), or oral ketoconazole.

294

295

296 **Detailed Study Methods**

297 Study methods are described in detail in **Figure 2** and the accompanying Spirit Figure (**Figure**
298 **3**). Following informed consent, volunteers will be screened to determine whether they meet the
299 study enrollment criteria. Initial screening will include medical history including concomitant
300 medications, and physical exam, structured clinical interview for DSM-5 psychiatric disorders,
301 COVID-19 antibody tests, EKG, baseline spirometry to assess pulmonary function, and clinical
302 safety laboratory testing to include serum chemistries, complete blood count, and urinalysis.
303 Subjects will have thyroid functions tests (TFTs), highly sensitive C-reactive protein (CRP),
304 cardiac specific troponins and pro-BNP levels (the latter to assess for myocarditis) at screening
305 only. Females will have a urine test for β -hCG at screening, and if positive, serum β -hCG
306 (Figure 2 and 3). The initial screening will be valid for 60 days prior to participation in a nested
307 randomized placebo-controlled trial of ivabradine to reduce heart rate and improve symptoms
308 (nested RCT).

309 After the initial Cohort Screening visit, volunteers meeting criteria will return for enrollment into
310 the overall LHC cohort and screening for the nested RCT (visit 2). Enrolled volunteers will
311 undergo whole genome sequence analysis to look for biomarkers of LHC risk, along with multi-
312 omic analysis. Volunteers will have orthostatic vital signs, an interval medical history, EKG,
313 immunologic assays, psychosocial, quality of life, and cognitive surveys; complete cognitive
314 performance tasks; undergo metabolic testing, and have concomitant medications reviewed.
315 Volunteers enrolled to the overall study cohort will be screened for enrollment in the nested RCT
316 for POTS. Volunteers will be provided with ambulatory electrocardiographic and vital signs
317 monitoring devices at enrollment, and complete of a detailed symptom diary for review by study

318 investigators after 1 week of monitoring. Investigators will determine whether volunteers meet
319 criteria to participate in the nested (RCT) of ivabradine to reduce heart rate and improve POTS
320 symptoms. The inclusion criteria for the nested RCT are the same as the overall cohort plus:
321 POTS diagnosed based on increased heart rate from supine to standing \geq 30 beats per minute and
322 $<$ 20 mm Hg drop in systolic or $<$ 10 mmHg drop in diastolic blood pressure. Volunteers
323 diagnosed with IST with or without LHC based on a 24-hour mean heart rate of 90 beats per
324 minute or more (in sinus rhythm) will also be included. Females of childbearing age must be
325 willing to use a highly effective form of contraceptive with $<$ 1% failure rate or practice
326 abstinence for the RCT duration.

327 **Treatment Intervention**

328 Ivabradine (Procoralan) at a starting dose of 5mg twice per day will be compared to placebo in
329 addition to otherwise appropriate medical care. The dose will be adjusted based on individual
330 heart rate response in accordance with the approved product label.

331 **Randomization, Allocation, and Blinding**

332 Study drug will be allocated to treatment groups by an unblinded research pharmacist. Treatment
333 allocation and randomization will be determined in advance using time-blocked randomization
334 with blocks of three. Allocation will be concealed from the volunteers and study team with
335 treatment assignments predetermined by unblinded personnel not otherwise engaged in study
336 procedures. Test article will be concealed from both subjects and investigators by placing
337 medications at predetermined doses in gel capsules. For active treatment, 2.5mg dose units will
338 be encapsulated with a pharmaceutically inactive compound (e.g. microcrystalline cellulose),
339 while the placebo group will receive capsules with only the inactive compound.

340 **Data Collection**

341 *Clinical Assessments*

342 Orthostatic vital signs will be collected with volunteers sitting, standing, and lying down with 5
343 minutes between each measurement. Head-up tilt-table (HUTT) testing will be performed with
344 the volunteer in the fasted state with heart rate and blood pressure monitoring. HUTT will be
345 considered abnormal if the volunteer has an increase in heart rate of 30 beats per minute over
346 baseline with accompanying symptoms of orthostatic intolerance. A history and physical exam
347 at screening will include demographics (age, sex, race, ethnicity), medical history to include
348 documenting the volunteer's history of COVID-19, vital signs and clinically significant
349 abnormal physical findings. A brief interval medical history and targeted physical exam to
350 include adverse event assessment will be performed at subsequent visits. Adverse events for
351 those enrolled in the RCT will be assessed for severity and treatment relatedness using the
352 Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

353 Volunteers will have supine 12 lead electrocardiograms after a five-minute period of rest.
354 Continuous ambulatory blood pressure and electrocardiographic monitoring will be measured
355 using appropriate FDA-cleared device(s). Subjects enrolled to the nested RCT will continue to
356 have these assessments during the study through month 3. Subjects not enrolled to the RCT will
357 have these performed for 1 week starting at the second screening visit for the nested RCT and 1
358 week at least 2 weeks prior to study discharge. Volunteers will maintain a cardiac symptom diary
359 while they have ambulatory EKG and vital signs monitoring. Spirometry will be performed to
360 assess pulmonary function along with a Dyspnea-12 score which will serve as a key indicator of
361 potential confounding by residual and/or pre-existing respiratory illness. An echocardiogram

362 will be performed at baseline for all those enrolled to the nested RCT to exclude subjects with
363 left ventricular ejection fractions <40%.

364 *Dose Adjustment*

365 For those enrolled in the RCT, ivabradine dose will be adjusted based on treatment response
366 according to the label. Those taking placebo will have adjustments made using test article
367 intended to match active treatment based on appearance.

368 *Psychosocial, Quality of Life, and Cognitive Factors Assessment*

369 Volunteers will complete a series psychosocial and quality of life of surveys. The Short Form
370 Health Survey (SF-36 v2) includes coherent and easily administered items evaluating quality of
371 life in physical, emotional, and social domains (51). The Patient Health Questionnaire-SADS
372 (PHQ-SADS) is a 30-item self-report measure incorporating items from the PHQ-8 (depression
373 symptoms), GAD-7 (generalized anxiety disorder symptoms), and PHQ-15 (somatic symptoms)
374 (52). Volunteers also will complete the self-report Depression Anxiety Stress Scale-21 (DASS-
375 21) (53), a questionnaire assessing stress, depression, and anxiety symptoms experienced during
376 the past week. The Patient-Reported Outcomes Measurement Information System (PROMIS)
377 Cognitive Function Short Form-8a will assess perceived cognitive function over the past week
378 (54). Modules from the Structured Clinical Interview for DSM-5 disorders – research version
379 (SCID-5-RV) will be used to evaluate psychiatric disorders (e.g., mood, anxiety, somatic
380 disorders, etc.) and assess possible psychological bases for somatic complaints (55). Finally
381 volunteers will complete the NIH Toolbox Cognition Battery (56), a series of cognitive tasks to
382 assess working memory, episodic memory, immediate recall, processing speed, attention, and
383 executive function. (Figure 2 and 3.)

384 ***Hematology Assays***

385 Clinical and research laboratory assays (PT, APTT, factor VIII:C, total fibrinogen, D-dimer,
386 thrombin generation assay and thromboelastometry (ROTEM), gamma prime fibrinogen, von
387 Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity and soluble
388 thrombomodulin) will quantify and characterize specific markers of dysregulated coagulation
389 and immunothrombosis.

390 ***Genomic Analysis***

391 PAXGene Blood tubes will be collected for genomic and transcriptomic profiling. For whole
392 genome sequencing, genomic DNA will be isolated and used as input for PCR-free library
393 preparation using a ligation-based method on automated liquid handling platforms. Sequencing
394 libraries will be sequenced using Illumina NovaSeq 6000 platforms with paired-end 150bp reads.
395 Raw reads will be demuxed, aligned to a reference genome and genomic variants will be called
396 using a DRAGENv4.0 graph genome and machine learning enabled pipeline. Variants will be
397 annotated and interpreted using a phenotype-aware pipeline using Genomiser and used as input
398 for polygenic risk score calculation from selected polygenic score sources from the PGS catalog
399 and used for comparative analysis with control-matched general population scores to identify
400 candidate traits associated with POTS/ITS.

401 ***Multi-omic Assays***

402 Peripheral blood mononuclear cells (PBMCs) will be collected to assess for transcription,
403 translation and expression of key host and disease factors. Metabolomics will be evaluated along
404 with transcriptome and plasma for proteomics.

405 ***Immunologic Assays***

406 Serology and cytokines will be assessed in serum, with PBMCs collected for cell-based
407 immunity assays to potentially include studies of T and NK cells. Plasma levels of histamine,
408 tryptase, and prostaglandin D2 will be measured 15 minutes before and shortly after orthostasis
409 testing to assess for mast cell and basophil degranulation. Additionally, biomarker levels
410 including IL-1 receptor antagonist (IL-1Ra), adiponectin, and cholinesterases may be evaluated
411 at baseline while participants are in the supine position to determine if these inflammatory and
412 metabolic markers are altered in individuals with LHC and POTS. These measurements will be
413 made on the same plasma samples but only in the supine position.

414 ***Basophil Activation in Response to CGRP and Substance P***

415 Basophil Activation in response to CGRP and substance P, as well as basophil sensitivity to
416 activation via the IgE signaling pathway, will be measured before starting the study drug and
417 prior to orthostasis testing. Activation assays may be repeated at the 3-month time point.

418 ***Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis***

419 Drug levels of ivabradine and relevant metabolites will be analyzed. Results will not be included
420 in the study database until after the first 3 months of the study have been completed for all nested
421 RCT subjects to maintain blinding. For those subjects assigned to placebo, at the completion of 3
422 months, individuals will be offered cross-over to active drug with participation in a rich-PK
423 sampling study to establish population PK-PD data for ivabradine. The first dose of ivabradine
424 (5mg) will be administered followed by serial blood PK specimens at pre-dose (0 hour; within 1
425 hour prior to dosing), and at 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing.

426 ***Unblinded Data Safety Monitoring Board (DSMB) Assessment***

427 Individual treatment effectiveness will be assessed on a rolling basis by an independent,
428 unblinded DSMB as nested RCT subjects approach completion of the first 3 months of the study.
429 Placebo-treated volunteers will be offered treatment at month 3 with an additional 9 months of
430 follow-up. Treated subjects will be evaluated for treatment benefit and continued at the identified
431 effective dose as appropriate. The DSMB will include the Research Monitor and 3 physicians.

432 ***Data Storage and Handling***

433 Study data will be recorded in electronic case report forms (CRFs) using the Research Electronic
434 Data Capture system (REDCap). De-identified data will be directly captured from diagnostic
435 devices including ultrasound images, continuous ambulatory vital signs and/or cardiac telemetry
436 locally stored on password-protected devices.

437 ***Sample Size Justification and Statistical Analysis***

438 Up to 200 evaluable subjects will be enrolled in the general LHC cohort. Study recruiting will
439 be implemented to enrich for volunteers with common clinical features of POTS. At least 20% of
440 those recruited are expected to have appropriate POTS or IST symptoms for enrollment to the
441 nested RCT (ivabradine vs. placebo). The design is estimated to yield an RCT study population
442 of at least 40 evaluable subjects. Drop-outs in all cohorts may be replaced. With at least 36
443 subjects completing the RCT at 2:1 allocation of treatment to placebo, the study will have 80%
444 power to identify a difference in standing heart rate at 3 months from 90 bpm in the placebo
445 group compared to 80 bpm in the treated group at the 0.05 significance level.

446 Data will be analyzed using Stata, R, or another equivalent statistical computing package.
447 Participant demographic and clinical characteristics will be characterized. Percentages and
448 means (with standard deviations) will be calculated for categorical and continuous variables,

449 respectively. We will assess differences in characteristic distribution by group using Chi-square
450 and t-tests (or Fisher's exact test for small sample sizes) as appropriate. Group differences will
451 be determined for outcomes using multilevel linear (for continuous variables) and logistic
452 regression models. Results will be reported using odds ratios (ORs) for binary outcomes and
453 regression coefficients for continuous outcomes. Association estimates will include 95% CIs. A
454 two-tailed error rate of $\alpha = .05$ will be the threshold for statistical significance.

455

456 **Discussion**

457 Since the initial reports emerged on autonomic dysfunction associated with long-haul COVID-
458 19, substantial progress has been made in better characterizing associated sequelae. Despite
459 these recent gains, a great deal remains poorly understood regarding how best to evaluate and
460 treat a lengthy list of potential symptoms and syndromes (4, 57). Amidst this quandary, POTS
461 has emerged as the most common form of autonomic dysfunction associated with LHC, with as
462 many as 2.5% of those with LHC affected (58). Pre-COVID, longitudinal studies revealed that
463 while often self-limited, residual POTS symptoms may persist for 5 years or longer.

464 Despite diagnostic advances, efforts to differentiate POTS from other autonomic syndromes
465 remain imperfect. This is due in part to the wide array of organ systems and functions controlled
466 by the autonomic nervous system (ANS). The most common cardiovascular findings may
467 include tachycardia and hypertension from increased sympathetic tone, orthostatic hypotension
468 from decreased baroreceptor and chemoreceptor reflex sensitivity, and reduced heart rate
469 variability (59). Commonly recommended clinical diagnostic tests to evaluate autonomic
470 dysfunction include Valsalva maneuvers, supine and standing vital signs measurements or head-

471 up tilt table testing (HUTT), a 6-minute walk test, deep breathing, and ambulatory EKG testing.
472 Other tests including skin biopsies for evaluation of peripheral nerve inflammation, and
473 emerging wearable device measurements have also been suggested. A range of questionnaires
474 have also been employed including the COMPASS-31, Vanderbilt Orthostatics Symptom Score
475 (VOSS), PROMIS-29, and others (58). In the present study, we have selected a subset of tests in
476 the interests of time, simplicity, and the ability to enroll and retain subjects. Planned tests include
477 HUTT (or supine/standing vital signs for those unable to complete HUTT), ambulatory EKG
478 monitoring, and the COMPASS-31 survey for autonomic dysfunction. Volunteers will be
479 monitored using an advanced automated ambulatory vital signs monitor recently approved by
480 FDA in order to aid in diagnosis (60).

481 Difficulties in diagnosis can compound the disability and demoralization suffered by POTS
482 patients. An estimated 10% of POTS sufferers may be unable to return to work and 40% have
483 residual deficits (61). The present study will prospectively evaluate 200 LHC volunteers with a
484 nested RCT to assess the impact of ivabradine on heart rate and symptoms in those meeting
485 diagnostic criteria for two important types of autonomic dysfunction, POTS and inappropriate
486 sinus tachycardia (IST). Our approach will include an integrated clinical, psychological and
487 laboratory evaluation of a cohort of patients enriched for symptoms and signs consistent with
488 autonomic dysfunction. A comparator group of 50 volunteers with documented COVID-19 but
489 without LHC will be enrolled to better identify the risk factors for LHC and autonomic
490 dysfunction. The comparator group will also be evaluated for POTS/IST and eligible for
491 inclusion in the nested RCT if present.

492 A large number of interventions have been proposed for POTS. Standard of care remains limited
493 and currently includes remedies such as compression garments, hydration and fludrocortisone to
494 treat hypovolemia, drugs like midodrine to treat hypotension, and propranolol for tachycardia
495 and increased sympathetic tone. Among other proposed experimental interventions such as
496 intravenous immune globulin as a general anti-inflammatory and SSRIs for affective
497 components, ivabradine has been proposed to lower heart rate and alleviate associated
498 symptoms. Ivabradine is a unique specific modulator of sinus node automaticity that acts
499 through specific blockade of the I_{funny} channel, whose expression is relatively restricted to
500 cardiac nodal tissue. Other commonly used rate lowering agents including beta blockers and non-
501 dihydropyridine calcium channel blockers have off-target effects on cardiac contractility, blood
502 pressure and/or bronchial tone. Limited evidence to date indicates that ivabradine may be
503 effective for both POTS and IST by reducing inappropriately elevated heart rate in these
504 conditions. Nevertheless, most of the data regarding ivabradine in POTS is anecdotal, with one
505 small RCT demonstrating benefit to date (50). This study will add to the understanding of the
506 potential therapeutic value of ivabradine in post-viral dysautonomia. Ivabradine's current scope
507 remains limited to the management of tachycardia associated with stable angina and heart failure
508 not fully managed by beta blockers.

509 In addition to the primary aims, the study will contribute to identifying risk factors and better
510 understanding pathophysiological processes, laying the groundwork for further exploration. The
511 pathophysiologic basis and underlying mechanisms of disease remain poorly defined at present,
512 though recent progress has been made (44). In the present study, we aim to take a
513 multidisciplinary approach to better understand the diagnosis and management of LHC-
514 associated POTS. LHC/POTS is believed to be caused by multiple pathophysiological processes

515 including immune dysregulation, hematologic dysfunction, and dysautonomia. In our study, the
516 risk factor evaluation will assess for hematological, immunological, and metabolic anomalies
517 underlying the development of autonomic dysregulation. Genomic and multi-omic analysis will
518 probe for genotypic and phenotypic risk factors for dysautonomia. Furthermore, symptoms of
519 POTS/IST remain broadly heterogeneous, including overlapping psychological and psychiatric
520 manifestations, for e.g., insomnia, depression, fatigue, memory loss. The study will incorporate
521 evaluation of psychosocial, quality of life, and cognitive factors to better understand
522 psychological and cognitive symptoms, and determine their interplay with physiologic responses
523 to LHC.

524 Study of a complex disease with an intricate follow-up plan is bound to face practical
525 implementation challenges. First, there is no established consensus for LHC diagnosis. Non-
526 specific symptoms such as fatigue might not prompt patients to seek medical care. As a result,
527 LHC remains an underdiagnosed condition, thus, reducing the pool of potential patients available
528 for recruitment. We aim to overcome this challenge through use of a comprehensive diagnostic
529 strategy, to include the use of ambulatory measurements. Our recruitment strategy aims to
530 combine community outreach including local healthcare providers to effectively identify and
531 refer potential participants. Compliance with a host of study procedures and visits is a generic
532 challenge for clinical research but may be compounded by disability and other challenges faced
533 by POTS sufferers. Appropriate guidance and participant education will be key in ensuring
534 successful adherence. The diagnostic complexity of POTS and related dysautonomia syndromes
535 is also a potential limitation, as we have opted for an implementable subset of diagnostic tests
536 from among the wide array available. Our hope is that use of multiple modalities to include
537 ambulatory monitoring will ensure an adequate number of volunteers are enrolled in the RCT.

538 We estimate 20-25% of those with POTS-like symptoms presenting for the study will actually
539 have POTS, but these could prove to be substantial over- or under-estimates. Blinding a study
540 using a rate-lowering agent may be challenging as well, particularly where placebo-treated
541 subjects experience no benefit and are at risk for non-compliance or drop-out.

542 The management of LHC-associated POTS, a complex multifactorial condition, remains an
543 emerging area of study and an ongoing challenge for patients and clinicians alike. The present
544 study aims to add to the rapidly expanding LHC knowledge base, and explore one of several
545 proposed interventions for LHC-associated cardiovascular autonomic dysfunction. We aim to
546 accurately assess the effectiveness of ivabradine and its proper use in the management of LHC
547 complicated by POTS. In so doing, we hope to provide a more solid evidence base for those
548 struggling with this debilitating condition.

549 **Trial status**

550 This study is conducted under protocol IRB # USUHS.2022-094 approved in April 2022. The
551 recruitment began on May 5th 2023 and is expected to be completed within a year in May 2024.

552

553

554

555

556

557

558

559

560 **Table 1. COVIVA Study Objectives.**

561

Objectives	Study Endpoints/Milestones
1. Assess frequency and severity of fatigue, dyspnea, headache, confusion and other suggestive symptoms in volunteers with and without LHC; measure occurrence of clinically confirmed POTS or IST—in relation to symptoms	Proportions of LHC and non-LHC volunteers with POTS; disease severity based on composite physiologic (ambulatory EKG, vital signs, orthostatics, Objective 3) and well-being assessments (Objective 5)
2. Assess whether treatment with ivabradine will significantly reduce heart rate; improve symptoms and quality of life among volunteer with POTS or similar dysautonomia	Primary endpoint for the nested ivabradine RCT - reduction in standing heart rate at three months. A small cross-over RCT in POTS patients without COVID-19 history found ivabradine reduced standing heart rate ~16 bpm between treated and placebo groups (see text)
3. Determine whether wearable automated ambulatory monitoring with existing FDA-approved devices will improve diagnostic accuracy for POTS	The differential proportion of individuals diagnosed with POTS using conventional (in-office) and wearable diagnostic methods
4. Determine the degree to which LHC induces autonomic instability and its associations with induced inflammation and/or dysregulation	Degree and severity of POTS as in Objectives 1 and 3. Levels of circulating catecholamines before and after orthostatic maneuvers
5. Evaluate potential contribution of psychological symptoms and interplay between psychosocial and cognitive symptoms, quality of life, and physiologic responses induced by LHC	Changes in quality of life (SF-36); psychosocial functioning (PHQ-SADS, DASS-21 surveys); Structured Clinical Interview for DSM-5 disorders; cognitive function (PROMIS, NIH Toolbox)
6. Determine if LHC improves following subsequent vaccination and/or “breakthrough” COVID-19 infection	Changes in quality of life, symptom surveys and/or laboratory markers of infection in those vaccinated or contracting infection during the study

<p>7. Compare antibody and/or cellular immune responses to SARS-CoV-2 antigens in LHC patients and infected individuals without LHC</p>	<ol style="list-style-type: none"> 1. IgG antibodies to SARS-CoV-2 or the four major seasonal human coronaviruses (HCoV-OC43, HCoV-HKU1, HCoV-229E, or HCoV-NL63) 2. T-cell cytokine responses against SARS-CoV-2 3. Evaluate whether individuals with LHC have decreased immunoregulatory networks compared to infected individuals without LHC 4. Assess NK cell phenotypic/functional differences 5. Identify if POTS-related orthostasis is associated with mast cell degranulation and basophil activation product release (histamine, tryptase) 6. Evaluate whether basophil responsiveness to activation in response to mediators released by parasympathetic nerves (Calcitonin gene-related peptide (CGRP), Substance P) is different between individuals with POTS and those without.
<p>8. Assess whether markers of dysregulated blood coagulation (significantly correlated with immunothrombosis in severe COVID-19) persist in individuals with LHC</p>	<p>PT, APTT, factor VIII:C, total fibrinogen, D-dimer, thrombin generation, thromboelastometry (ROTEM); Exploratory - gammaprime fibrinogen, von Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity, soluble thrombomodulin</p>

562

563

564 **Figure Legends**

565 **Figure 1. Overall Study Schema.** A diagram of the general study design. The study will
 566 include an observational cohort with 250 volunteers including 200 with long-haul COVID and
 567 50 controls without LHC. Those from the observational cohort who are diagnosed with POTS
 568 will be randomized to a nested, placebo-controlled trial of ivabradine to control heart rate and
 569 improve symptoms. (POTS - Postural Orthostatic Tachycardia Syndrome; IST - Inappropriate
 570 Sinus Tachycardia; IVA - Ivabradine; SXS - Symptoms; HR - Heart Rate; BP - Blood Pressure).

571

572 **Figure 2. COVIVA Study Schedule of Events.** A listing of times and events for study procedures.

573

574 **Figure 3. COVIVA Study Spirit Figure**

575

576

577

578

579 **List of abbreviations**

580 ACE: Angiotensin Converting Enzyme

581 ANS: Autonomic Nervous System

582 CBC: Cell Blood Count

583 CGRP: Calcitonin Gene-Related Peptide

584 CIs: Confidence Intervals

585 CTCAE: Common Terminology Criteria for Adverse Events

586 COMPASS: Composite Autonomic Symptom Score

587 COVID-19: Coronavirus Disease 2019

588 CRFs: Case Report Forms

589 CRP: C - Reactive Protein

590 DASS-21: Depression Anxiety Stress Scale-21

- 591 DSMB: Data Safety Monitoring Board
- 592 DNA: Deoxyribonucleic Acid
- 593 DSM-V: Diagnostic and Statistical Manual of the DSM, 5th edition
- 594 EKG: Electrocardiogram
- 595 GAD: Generalized Anxiety Disorder
- 596 GPF: Gamma Prime Fibrinogen
- 597 FDA: Food and Drug Administration
- 598 HCN: Hyperpolarization-Activated Cyclic Nucleotide-Gated
- 599 HUTT: Head-Up Tilt-Table
- 600 IST: Inappropriate Sinus Tachycardia
- 601 LHC: Long-Haul' COVID-19
- 602 MSAS: Memorial Symptom Assessment Scale
- 603 MHS: Military Health System
- 604 NIH: National Institutes of Health
- 605 NK: Natural Killer
- 606 ORs: Odds Ratios
- 607 PBMCs: Peripheral Blood Mononuclear Cells
- 608 PHQ: Patient Health Questionnaire

- 609 POTS: Postural Orthostatic Tachycardia Syndrome

- 610 PT: Prothrombin Time

- 611 PTT: Partial Thromboplastin Time

- 612 PROMIS: Patient-Reported Outcomes Measurement Information System

- 613 RCT: Randomized Controlled Trial

- 614 REDCap: Research Electronic Data Capture system

- 615 SA: Sinoatrial

- 616 SCID-5: Structured Clinical Interview for DSM-5 Disorders

- 617 SF-36: Short Form Health Survey

- 618 SNPs: Single Nucleotide Polymorphisms

- 619 TFTs: Thyroid Functions Tests

- 620 TMPRSS2: Transmembrane Protease Serine-2

- 621 VOSS: Vanderbilt Orthostatics Symptom Score

- 622 VWF: Von Willebrand Factor

- 623

624 **Declarations**

625 *Ethics approval and consent to participate*

626 The study was approved by the Uniformed Services University of the Health Sciences
627 Institutional Review Board in June 2022 and registered with clinicaltrials.gov as NCT05481177.

628 Written informed consent will be obtained from all participants. A copy of the ethical approval
629 and consent have been submitted as an additional file.

630 ***Consent for publication***

631 Not applicable.

632 ***Competing Interest***

633 The authors have no conflicts of interest to disclose.

634 ***Funding***

635 This study is funded by the Defense Health Agency (DHA), Department of Defense through the
636 Uniformed Services University. Funds to perform the study were awarded through Cooperative
637 Agreements with The Metis Foundation (Award # HU00012120090) and Henry M. Jackson
638 Foundation for the Advancement of Military Medicine (Award # HU00012120087). The Funder
639 has no role in the in study design; collection, management, analysis, and interpretation of data;
640 writing of the report; or the decision to submit the report for publication.

641 ***Author's contribution***

642 DS is the Principal Investigator and MH the Protocol Chair and grant awardee; they conceived
643 the study, led the proposal and protocol development and drafted the manuscript. TA, JL, DB,
644 KA, LH, RM, BM, DS, KP, PK, ME, AM, MTK, EG, EM, KP and CD assisted in the design of
645 the development of the protocol as well as editing of the manuscript. DS, MH, BM, RM and STL
646 drafted and edited the manuscript. MH supervised the design and implementation of the study
647 and edited the manuscript. All authors read and approved the final manuscript.

648 ***Acknowledgements***

649 The authors would like to acknowledge our colleagues without whom the study would not have
650 been possible. From the Uniformed Services University Drs. Jacob Collen, Marian Tanofsky-
651 Kraft, Ian Stewart, Paige Waterman, Martin Evans, Benjamin Pierson, Milissa Jones, Monique
652 Hollis-Perry, Agnes Montgomery, Vivian Bauman, Katherine Thompson; Ms. Austin Pagani,
653 Annette Cunningham, and Debra Weed. From the US Army Medical Research Institute of
654 Infectious Diseases – Drs. Phillip Pittman, Erin Tompkins, Fernando Guerena and Ms. Carolyn
655 Holland. From the Henry M. Jackson Foundation for the Advancement of Military Medicine
656 Ms. Priscilla Kobi, Laurie Coran, Raquel Martinez, Heidi Adams, and Tabitha Shipmon. From
657 the Metis Foundation – Marlene Barrera, Stephanie Margaret Mayne, Timothy Suzich, Joya
658 Libbus, Keiko Fox, Holly Spinner, Isabel Thorstad, Hannah Repke, and Ashlee Simmons. From
659 the Walter Reed Army Institute of Research Dr. Daniel Selig. From the Armed Forces Research
660 Institute of Medical Sciences Drs. Pattaraporn Vanachayangul and Jeffrey Livezey. From the
661 Walter Reed National Military Medical Center Drs. Jessica Wong-Flores, Nikhil Hauprikar and
662 Wesley Campbell, and Mr. Victor Buckwold. From the US Army Research Institute of
663 Environmental Medicine Dr. Geoff Chin and from the Joint Program Executive Office of
664 Chemical and Biological Defense Dr. Anthony Cardile.

665

666 **References**

667

668 1. Long CVID or POST-COVID Conditions. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html?s_cid=11840:long%20term%20covid:sem.ga:p:RG:GM:gen:PTN:FY23)

669 [ncov/long-term-](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html?s_cid=11840:long%20term%20covid:sem.ga:p:RG:GM:gen:PTN:FY23)

670 [effects/index.html?s_cid=11840:long%20term%20covid:sem.ga:p:RG:GM:gen:PTN:FY23](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html?s_cid=11840:long%20term%20covid:sem.ga:p:RG:GM:gen:PTN:FY23).

671 Accessed 29 March 2023.

672 2. Mar PL, Raj SR. Postural Orthostatic Tachycardia Syndrome: Mechanisms and New
673 Therapies. *Annu Rev Med*. 2020;71:235-48. doi: 10.1146/annurev-med-041818-011630. Epub
674 2019 Aug 14. PMID: 31412221.

675 3. Is POTS a Long-Haul Post-COVID-19 Symptom? [https://www.acc.org/latest-in-](https://www.acc.org/latest-in-cardiology/articles/2021/03/10/20/13/is-pots-a-long-haul-post-covid-19-symptom)
676 [cardiology/articles/2021/03/10/20/13/is-pots-a-long-haul-post-covid-19-symptom](https://www.acc.org/latest-in-cardiology/articles/2021/03/10/20/13/is-pots-a-long-haul-post-covid-19-symptom). Accessed 29
677 March 2023.

678 4. Raj SR, Arnold AC, Barboi A. Long-COVID postural tachycardia syndrome: an
679 American Autonomic Society statement. *Clin Auton Res*. 2021;31(3):365-8. doi:
680 10.1007/s10286-021-00798-2. Epub 2021 Mar 19. PMID: 33740207; PMCID: PMC7976723.

681 5. Blomberg B, Mohn KG, Brokstad KA. COVID in a prospective cohort of home-isolated
682 patients. *Nat Med*. 2021;27(9):1607-13. doi: 10.1038/s41591-021-01433-3. Epub 2021 Jun 23.
683 PMID: 34163090; PMCID: PMC8440190.

684 6. Grubb BP. Autonomic Dysfunction as a Consequence of COVID-19 Infection: A New
685 Twist on an Old Problem. *J Am Coll Cardiol*. 2022;79(23):1331-2332. doi:
686 10.1016/j.jacc.2022.04.007. PMID: 35680184; PMCID: PMC8972341.

687 7. Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology
688 and management. *J Intern Med*. 2019;285(4):352-66. doi: 10.1111/joim.12852. Epub 2018 Nov
689 23. PMID: 30372565.

690 8. Sheldon RS, Grubb BP 2nd, Olshansky B. 2015 heart rhythm society expert consensus
691 statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus
692 tachycardia, and vasovagal syncope. *Heart Rhythm*. 2015;12(6):41-63. doi:
693 10.1016/j.hrthm.2015.03.029. Epub 2015 May 14. PMID: 25980576; PMCID: PMC5267948

- 694 9. Dixit NM, Churchill A, Nsair A. Post-Acute COVID-19 Syndrome and the
695 cardiovascular system: What is known? *Heart J Plus.* 2021;5:100025. doi:
696 10.1016/j.ahjo.2021.100025. Epub 2021 Jun 24. PMID: 34192289; PMCID: PMC8223036.
- 697 10. Nalbandian A, Sehgal K, Gupta A. Post-acute COVID-19 syndrome. *Nat Med.*
698 2021;27(4):601-15. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22. PMID: 33753937;
699 PMCID: PMC8893149.
- 700 11. Ramakrishnan RK, Kashour T, Hamid Q. Unraveling the Mystery Surrounding Post-
701 Acute Sequelae of COVID-19. *Front Immunol.* 2021;12 :686029. doi:
702 10.3389/fimmu.2021.686029. PMID: 34276671; PMCID: PMC8278217.
- 703 12. Crook H, Raza S, Nowell J. Long covid-mechanisms, risk factors, and management.
704 *BMJ.* 2021;374:n1648. doi: 10.1136/bmj.n1648. Erratum in: *BMJ.* 2021 Aug 3;374:n1944.
705 PMID: 34312178.
- 706 13. Ståhlberg M, Reistam U, Fedorowski A. Post-COVID-19 Tachycardia Syndrome: A
707 Distinct Phenotype of Post-Acute COVID-19 Syndrome. *Am J Med.* 2021;134(12):1451-6. doi:
708 10.1016/j.amjmed.2021.07.004. Epub 2021 Aug 11. PMID: 34390682; PMCID: PMC8356730.
- 709 14. Roe K. A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several
710 categories of COVID-19 patients. *J Neurosci Res.* 2021;99(10):2367-76. doi: 10.1002/jnr.24917.
711 Epub 2021 Jul 19. PMID: 34288064; PMCID: PMC8427009.
- 712 15. Kohno R, Cannom DS, Olshansky B. Mast Cell Activation Disorder and Postural
713 Orthostatic Tachycardia Syndrome: A Clinical Association. *J Am Heart Assoc.*
714 2021;10(17):e021002. doi: 10.1161/JAHA.121.021002. Epub 2021 Aug 16. PMID: 34398691;
715 PMCID: PMC8649306.
- 716 16. Mazzitelli I, Bleichmar L, Ludueña MG. Immunoglobulin G Immune Complexes May
717 Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019. *J Infect*
718 *Dis.* 2021;224(4):575-85. doi: 10.1093/infdis/jiab174. PMID: 34398243; PMCID: PMC8083460.
- 719 17. Wang TT, Ravetch JV. Immune complexes: not just an innocent bystander in chronic
720 viral infection. *Immunity.* 2015;17(42):213-15. doi: 10.1016/j.immuni.2015.01.022. PMID:
721 25692698.
- 722 18. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated
723 intravascular coagulation. *Int J Hematol.* 2021;113(1):45-57. doi: 10.1007/s12185-020-03029-y.
724 Epub 2020 Nov 7. PMID: 33161508; PMCID: PMC7648664.

- 725 19. Mancini I, Baronciani L, Artoni A. The ADAMTS13-von Willebrand factor axis in
726 COVID-19 patients. *J Thromb Haemost.* 2021;19(2):513-21. doi: 10.1111/jth.15191. Epub 2020
727 Dec 18. PMID: 33230904; PMCID: PMC7753796.
- 728 20. Ward SE, Fogarty H, Karampini E. ADAMTS13 regulation of VWF multimer
729 distribution in severe COVID-19. *J Thromb Haemost.* 2021;19(8):1914-21. doi:
730 10.1111/jth.15409. Epub 2021 Jun 20. PMID: 34053187; PMCID: PMC8237059.
- 731 21. Oikonomou E, Souvaliotis N, Lampsas S. Endothelial dysfunction in acute and long
732 standing COVID-19: A prospective cohort study. *Vascul Pharmacol.* 2022;144:106975. doi:
733 10.1016/j.vph.2022.106975. Epub 2022 Mar 3. PMID: 35248780; PMCID: PMC8893931.
- 734 22. Farrell DH, Hudkins M, Hamilton H. Extreme gammaprime levels in COVID-19
735 patients. *MedRxiv.* 2022. <https://doi.org/10.1101/2022.01.20.22269321>.
- 736 23. Fogarty H, Townsend L, Morrin H. Persistent endotheliopathy in the pathogenesis of
737 long COVID syndrome. *J Thromb Haemost.* 2021;19(10):2546-53. doi: 10.1111/jth.15490. Epub
738 2021 Sep 12. PMID: 34375505; PMCID: PMC8420256.
- 739 24. Macrae FL, Swieringa F, Heemskerk JWM. High fibrinogen gamma' levels in patient
740 plasma increase clot formation at arterial and venous shear. *Blood Adv.* 2021;5(17):3468-77.
741 doi: 10.1182/bloodadvances.2020003346. PMID: 34438442; PMCID: PMC8525222.
- 742 25. Marshall M. The lasting misery of coronavirus long-haulers. *Nature.* 2020;585:339-41.
743 doi: 10.1038/d41586-020-02598-6. PMID: 32929257.
- 744 26. Heath C, Sommerfield A, von Ungern-Sternberg BS. Resilience strategies to manage
745 psychological distress among healthcare workers during the COVID-19 pandemic: A narrative
746 review. *Anaesthesia.* 2020;75:1634-371. doi: 10.1111/anae.15180. Epub 2020 Jul 3. PMID:
747 32534465; PMCID: PMC7323405.
- 748 27. Mazza C, Ricci E, Biondi S. Nationwide Survey of Psychological Distress among Italian
749 People during the COVID-19 Pandemic: Immediate Psychological Responses and Associated
750 Factors. *Int J Environ Res Public Health.* 2020;17:3165. doi: 10.3390/ijerph17093165. PMID:
751 32370116; PMCID: PMC7246819.
- 752 28. Giusti EM, Pedroli E, D'Aniello GE. The Psychological Impact of the COVID-19
753 Outbreak on Health Professionals: A Cross-Sectional Study. *Front Psychol.* 2020;11:1684. doi:
754 10.3389/fpsyg.2020.01684. PMID: 32754102; PMCID: PMC7366071.

- 755 29. Pandey D, Bansal S, Goyal S,. Psychological impact of mass quarantine on population
756 during pandemics-The COVID-19 Lock-Down (COLD) study. PLoS ONE. 2020 Oct
757 22;15(10):e0240501. doi: 10.1371/journal.pone.0240501. PMID: 33091020; PMCID:
758 PMC7580982.
- 759 30. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental
760 Disorders, Fifth Edition (DSM-5). American Psychiatric Association; 2013.
- 761 31. Orrù G, Bertelloni D, Diolaiuti F. Long-COVID Syndrome? A Study on the Persistence
762 of Neurological, Psychological and Physiological Symptoms. Healthcare (Basel).
763 2021;13(5):575. doi: 10.3390/healthcare9050575. PMID: 34068009; PMCID: PMC8152255.
- 764 32. Graham EL, Clark JR, Orban ZS. Persistent neurologic symptoms and cognitive
765 dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol. 2021;
766 8(5):1073-1085. doi: 10.1002/acn3.51350. Epub 2021 Mar 30. PMID: 33755344; PMCID:
767 PMC8108421.
- 768 33. Singh H, Choudhari R, Nema V. ACE2 and TMPRSS2 polymorphisms in various
769 diseases with special reference to its impact on COVID-19 disease. Microb Pathog
770 2021;150:104621. doi: 10.1016/j.micpath.2020.104621. Epub 2020 Dec 2. PMID: 33278516;
771 PMCID: PMC7709597.
- 772 34. Glotov OS, Chernov AN, Scherbak SG. Genetic Risk Factors for the Development of
773 COVID-19 Coronavirus Infection. Russ J Genet. 2021;57:878-92. doi:
774 10.1134/S1022795421080056. Epub 2021 Aug 30. PMID: 34483599; PMCID: PMC8404752.
- 775 35. Srivastava A, Bandopadhyay A, Das D. Genetic association of ACE2 rs2285666
776 polymorphism with COVID-19 spatial distribution in India. Front Genet 2020; 11:564741. doi:
777 10.3389/fgene.2020.564741. PMID: 33101387; PMCID: PMC7545580.
- 778 36. Ravikanth V, Sasikala M, Naveen V,. A variant in TMPRSS2 is associated with
779 decreased disease severity in COVID-19. Meta Gene 2021;25 :100930. doi:
780 10.1016/j.mgene.2021.100930. Epub 2021 May 28. PMID: 34075330; PMCID: PMC8161869.
- 781 37. Dobrijevic Z, Robajac D, Gligorijevic N. The association of ACE1, ACE2, TMPRSS2,
782 IFITM3 and VDR polymorphisms with COVID-19 severity: A systematic review and meta-
783 analysis. EXCLI J. 2022;21:819-39. doi: 10.17179/excli2022-4976. PMID: 35949487; PMCID:
784 PMC9360474.

- 785 38. Gupta K, Kaur G, Pathak T. Systematic review and meta-analysis of human genetic
786 variants contributing to COVID-19 susceptibility and severity. *Gene*. 2022;844 :146790. doi:
787 10.1016/j.gene.2022.146790. Epub 2022 Aug 17. PMID: 35987511; PMCID: PMC9384365.
- 788 39. Martínez-Gómez LE, Herrera-López B, Martinez-Armenta C. ACE and ACE2 gene
789 variants are associated with severe outcomes of COVID-19 in men. *Immunol*. 2022;13 :812940.
790 doi: 10.3389/fimmu.2022.812940. PMID: 35250987; PMCID: PMC8892378.
- 791 40. Wulandari L, Hamidah B, Pakpahan C. Initial study on TMPRSS2 p. Val160Met genetic
792 variant in COVID-19 patients. *Hum Genom*. 2021; 15(1):29. doi: 10.1186/s40246-021-00330-7.
793 PMID: 34001248; PMCID: PMC8127183..
- 794 41. Saengsiwaritt W, Jittikoon J, Chaikledkaew U. polymorphisms of ACE1, ACE2, and
795 TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. *Rev*
796 *Med Virol*. 2022;32(4):e2323. doi: 10.1002/rmv.2323. Epub 2022 Jan 8. PMID: 34997794.
- 797 42. Ni W, Yang X, Yang D. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
798 *Crit Care* 2020; 24(1):422. doi: 10.1186/s13054-020-03120-0. PMID: 32660650; PMCID:
799 PMC7356137.
- 800 43. Gheblawi M, Wang K, Viveiros A. Angiotensin-Converting Enzyme 2: SARS-CoV-2
801 receptor and regulator of the renin-angiotensin system. *Circ Res* 2020; 126(10):1456-1474. doi:
802 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8. PMID: 32264791; PMCID:
803 PMC7188049..
- 804 44. Castanares-Zapatero D, Chalon P, Kohn L. Pathophysiology and Mechanism of Long
805 COVID: A Comprehensive Review. *Ann Med* 2022; 54(1):1473-1487. doi:
806 10.1080/07853890.2022.2076901. PMID: 35594336; PMCID: PMC9132392.
- 807 45. PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation
808 profiling of long COVID and association with 1-year recovery following hospitalisation in the
809 UK: A prospective observational study. *Lancet Respir Med* 2022; 10(8):761-775. doi:
810 10.1016/S2213-2600(22)00127-8. Epub 2022 Apr 23. Erratum in: *Lancet Respir Med*. 2022 Jul
811 26;; PMID: 35472304; PMCID: PMC9034855.
- 812 46. Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G. Genetic Association between
813 ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms
814 with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors *Genes (Basel)*.
815 2022;13(11):1935. doi: 10.3390/genes13111935. PMID: 36360172; PMCID: PMC9690177.

- 816 47. Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G. ACE1 rs1799752
817 polymorphism is not associated with long-COVID symptomatology in previously hospitalized
818 COVID-19 survivors. *J Infect.* 2023;86(3):e67-e69. doi: 10.1016/j.jinf.2022.12.026. Epub 2022
819 Dec 28. PMID: 36584771; PMCID: PMC9794395.
- 820 48. Fu Q, Vangundy TB, Shibata S. Exercise training versus propranolol in the treatment of
821 the postural orthostatic tachycardia syndrome. *Hypertension.* 2011;58(2):167-75.
822 doi: 10.1161/HYPERTENSIONAHA.111.172262. Epub 2011 Jun 20. PMID: 21690484;
823 PMCID: PMC3142863.
- 824 49. Raj SR, Guzman JC, Harvey P. Canadian cardiovascular society position statement on
825 postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic
826 intolerance. *Canadian Journal of Cardiology.* 2020;36(3):357-72. doi:
827 10.1016/j.cjca.2019.12.024. PMID: 32145864.
- 828 50. Taub PR, Zadourian A, Lo HC, Ormiston CK. Randomized Trial of Ivabradine in
829 Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. *J Am Coll Cardiol*
830 2021;77:861-71. doi: 10.1016/j.jacc.2020.12.029. PMID: 33602468.
- 831 51. M Maruish, M Kosinski, J Bjorner. User's manual for the SF-36v2 health survey (3rd
832 ed.). Lincoln, RI: QualityMetric Incorporated. 2011.
- 833 52. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire Somatic,
834 Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp Psychiatry.*
835 2010;32:345-9.
- 836 53. Henry JD. The short-form version of the Depression Anxiety Stress Scales (DASS-21):
837 Construct validity and normative data in a large non-clinical sample. *British journal of clinical*
838 *psychology.* 2005;44(2):227-39. doi: 10.1016/j.genhosppsy.2010.03.006. Epub 2010 May 7.
839 PMID: 20633738.
- 840 54. Iverson GL, Marsh JM, Connors EJ. Normative reference values, reliability, and item-
841 level symptom endorsement for the PROMIS® v2.0 cognitive function-short forms 4a, 6a and
842 8a. *Archives of clinical neuropsychology.* 2021;36(7):1341-9. doi: 10.1093/arclin/aaal128.
843 PMID: 33454756.
- 844 55. First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-
845 5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA,
846 American Psychiatric Association; 2015.

- 847 56. Heaton RK, Akshoomoff N, Tulskey D. Reliability and validity of composite scores from
848 the NIH Toolbox Cognition Battery in adults. *Journal of the International Neuropsychological*
849 *Society*. 2014;20(6):588-98. doi: 10.1017/S1355617714000241. Epub 2014 Jun 24. PMID:
850 24960398; PMCID: PMC4103963.
- 851 57. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other
852 autonomic disorders after COVID-19 infection: a case series of 20 patients. *Immunologic*
853 *research*. 2021;69(2):205-11. doi: 10.1007/s12026-021-09185-5. Epub 2021 Mar 30. Erratum in:
854 *Immunol Res*. 2021 Apr 13;: PMID: 33786700; PMCID: PMC8009458
- 855 58. Carmona-Torre F, Mínguez-Olaondo A, López-Bravo A. Dysautonomia in COVID-19
856 patients: a narrative review on clinical course, diagnostic and therapeutic strategies. *Front*
857 *Neurol*. 2022;13:886609. doi: 10.3389/fneur.2022.886609. PMID: 35720084; PMCID:
858 PMC9198643.
- 859 59. Rangon CM, Krantic S, Moyses E. The vagal autonomic pathway of COVID-19 at the
860 crossroad of Alzheimer's disease and aging: a review of knowledge. *Journal of Alzheimer's*
861 *Disease Reports*. 2020;4(1):537-51. doi: 10.3233/ADR-200273. PMID: 33532701; PMCID:
862 PMC7835993.
- 863 60. Eisenkraft A, Maor Y, Constantini K. Trajectories of key physiological parameters in
864 COVID-19 patients using continuous remote monitoring and health AI.
865 [https://assets.researchsquare.com/files/rs-122775/v1/f62a1fd0-c0cf-4fba-829b-](https://assets.researchsquare.com/files/rs-122775/v1/f62a1fd0-c0cf-4fba-829b-f45d7f10a1e1.pdf?c=1631867089)
866 [f45d7f10a1e1.pdf?c=1631867089](https://assets.researchsquare.com/files/rs-122775/v1/f62a1fd0-c0cf-4fba-829b-f45d7f10a1e1.pdf?c=1631867089). Accessed 23 March 2023.
- 867 61. Sandroni P, Opfer-Gehrking TL, McPhee BR. Postural tachycardia syndrome: clinical
868 features and follow-up study. *Mayo Clinic Proceedings* 1999;74(11):1106-10. doi:
869 10.4065/74.11.1106. PMID: 10560597.

870

871

Tables and figures - Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for those with Postural Orthostatic Tachycardia Syndrome (The COVIVA Study).

Table 1. COVIVA Study Objectives.

#	Objective	Study Endpoints/Milestones
1.	To assess the frequency and severity of fatigue, dyspnea, headache, and confusion and other suggestive symptoms among volunteers with and without LHC and measure the occurrence of clinically confirmed POTS or IST—in relation to these symptoms	Proportions of LHC and non-LHC volunteers with postural orthostatic tachycardia syndrome (POTS), and disease severity based on a composite of physiologic (ambulatory EKG, vital signs, orthostatics, see Objective 3) and well-being assessments (see Objective 5).
2.	To assess whether treatment with ivabradine will significantly reduce heart rate and improve symptoms and quality of life among subjects manifesting typical POTS or similar autonomic dysregulation	The primary endpoint of the nested ivabradine RCT will be a reduction in standing heart rate at three months. Based on a prior small cross-over RCT in POTS patients without a history of COVID-19, a reduction of roughly 16 bpm in standing heart rate between the treated and placebo groups was observed. ¹
3.	To determine whether wearable automated ambulatory monitoring with existing FDA-approved devices will permit improved diagnostic accuracy for POTS.	The differential proportion of individuals diagnosed with POTS using conventional (in-office) and wearable diagnostic methods.
4.	To determine the degree to which LHC induces autonomic instability and whether it is associated with induced inflammation and/or dysregulation	Degree and severity of POTS as in Objectives 1 and 3. Levels of circulating catecholamines measured in the blood before and after orthostatic maneuvers.
5.	To evaluate potential contribution of psychological symptoms and the interplay between psychosocial symptoms, quality of life, cognitive symptoms, and physiologic responses induced by LHC.	Improvements/changes in quality of life measured by the SF-36, psychosocial functioning measured by the PHQ-SADS and DASS-21 surveys, and cognitive function measured by the PROMIS cognition survey and NIH Toolbox tasks.
6.	To determine whether LHC improves following vaccination (in the limited number of cases where late vaccination occurs) and/or “breakthrough” clinical COVID-19 infection.	Changes in longitudinal quality of life and symptoms surveys and/or laboratory markers of infection in those receiving vaccination or contracting infection during the study.
7.	Assess whether individuals with LHC have different antibody and/or cellular immune responses to SARS-CoV-2 antigens compared to infected individuals who did not develop LHC	<ol style="list-style-type: none"> 1. Assess whether IgG antibodies to SARS-CoV-2 or the four major seasonal human coronaviruses (HCoV- OC43, HCoV-HKU1, HCoV-229E, or HCoV-NL63) are associated with LHC. 2. Assess if T-cell cytokine responses against SARS- CoV-2 proteins are associated with LHC. 3. Evaluate whether individuals with LHC have decreased immunoregulatory networks compared to infected individuals who did not develop LHC. 4. Assess NK cell phenotypic/functional differences in LHC and non-LHC volunteers. 5. Identify if orthostasis in POTS disease is associated with release of mast cell degranulation and basophil activation products such as histamine and tryptase, and evaluate whether basophil responsiveness to activation in response to mediators released by parasympathetic nerves such as Calcitonin gene-related peptide (CGRP) and Substance P is different between individuals with

		POTS disease and those without.
8.	Assess whether specific plasma protein markers of dysregulated blood coagulation, which were significantly correlated with immunothrombosis in severe COVID-19, persist in individuals with LHC	Clinical or research-grade laboratory assays will quantify and characterize specific markers of dysregulated coagulation and immunothrombosis. Assays will include PT, APTT, factor VIII:C, total fibrinogen, D-dimer, thrombin generation assay and thromboelastometry (ROTEM) assay. Additional analytes may include gammaprime fibrinogen, von Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity and soluble thrombomodulin.

Figure 1. Overall Study Schema





Figure 2. COVIVA Study Schedule of Events



4. Week 1

1. Orthostatic Vital Signs
2. EKG
3. Interval H&P
4. Multi-omic assays (PBMC)
5. Hematology assays
6. Adverse events
7. Structured clinical interview
8. Concomitant Medications

RCT TRIAL

1. Enroll to RCT/Randomize
2. Dose Adjustments
3. Drug Levels

5. Week 2

1. Orthostatic Vital Signs
2. EKG
3. Interval H&P
4. Multi-omic assays (PBMC)
5. Adverse events
6. Ambulatory EKG
7. Ambulatory vital signs
8. Cardiac symptom diary
9. Concomitant Medications

RCT TRIAL

1. Dose Adjustments
2. Drug Levels

6. Month 1

1. Orthostatic Vital Signs
2. EKG
3. Interval H&P
4. Multi-omic assays (PBMC)
5. Safety labs
6. Basophil activation
7. Adverse events
8. Ambulatory EKG: review
9. Ambulatory vital signs: review
10. Cardiac symptom diary: review
11. Psychosocial, Quality of Life, and Cognitive Surveys
12. Cognitive performance tasks
13. Metabolic Testing
14. Concomitant Medications

RCT TRIAL

3. Dose Adjustments
4. Drug Levels



7. Month 3

1. Orthostatic Vital Signs
2. Covid 19 immunology testing
3. EKG
4. Interval H&P
5. PFTs/Dyspnea-12
6. Multi-omic assays (PBMC)
7. Safety labs
8. Immunologic assays
9. Basophil activation
10. Hematology assays
11. Adverse events
12. Ambulatory EKG
13. Ambulatory vital signs
14. Cardiac symptom diary
15. Structured clinical interview
16. Psychosocial, Quality of Life, and Cognitive Surveys Cognitive performance tasks
17. Metabolic Testing
18. Concomitant Medications

RCT TRIAL

1. Enroll to RCT/Randomize
2. Drug Levels/Dose Adjustments
3. Unblinded DSMB Assessment
4. PK/PD Assessment

8. Month 6

1. Orthostatic Vital Signs
2. Covid 19 immunology testing
3. EKG
4. Interval H&P
5. Multi-omic assays (PBMC)
6. Hematology assays
7. Adverse events
8. Psychosocial, Quality of Life, and Cognitive Surveys
9. Cognitive performance tasks
10. Metabolic Testing
11. Concomitant Medications

RCT TRIAL

1. Dose Adjustments
2. Drug Levels

9. Year 1

1. Orthostatic Vital Signs
2. Covid 19 immunology testing
3. EKG
4. Interval H&P
5. PFTs/Dyspnea-12
6. Multi-omic assays (PBMC)
7. Safety labs
8. Basophil activation
9. Adverse events
10. Ambulatory EKG
11. Ambulatory vital signs
12. Cardiac symptom diary
13. Psychosocial, Quality of Life, and Cognitive Surveys
14. Cognitive performance tasks
15. Metabolic Testing
16. Concomitant Medications

RCT TRIAL

1. Dose Adjustments
2. Drug Levels
3. Echocardiogram

Figure 3. COVIVA Study SPIRIT Figure

	STUDY PERIOD								
	Cohort screen (Up to day 60)	Cohort screen (Up to day 60)	Enroll RCT	Post-allocation					Final Assessment
	$-t_2$	$-t_1$	0	Week 1 t_1	Week 2 t_2	Month 1 t_3	Month 3 t_4	Month 6 t_5	Year 1 t_6
ASSESSMENTS									
Informed Consent	X								
Orthostatic vital signs	X	X	X	(X)	(X)	X	X	X	X
History & physical exam	X								
COVID-19 history	X								
Electrocardiogram (EKG)	X	X	X	(X)	(X)	X	X	X	X
Pulmonary Function Test /Dyspnea-12 Score	X						X		X
Structured clinical interview (DSM-5)	X			(X)			X		
Psychosocial, quality of life and cognitive surveys	X	X				X	X	X	X
Concomitant medications	X	X	X	(X)	(X)	X	X	X	X
COVID-19 Immunity testing		X					X	X	X
Enroll to Observational Cohort		X							
<i>Interval history/physical</i>		X	X	(X)	(X)	X	X	X	X

Multi-omic assays		X		(X)	(X)	X	X		X	
Genomic analysis		X								
Immunologic assays		X					X			
Hematology assays		X		(X)			X	X		
Ambulatory EKG		X	Review		(X)	Review	X		X	
Ambulatory vital signs		X	Review		(X)	Review	X		X	
Cardiac symptom diary		X	Review		(X)	Review	X		X	
Cognitive performance tasks		X						X	X	
Metabolic testing		X	(X)			(X)	(X)	(X)	X	
Safety labs			(X)			X	X		X	
Basophil activation*			(X)			X	X		X	
Adverse events			(X)	(X)	(X)	(X)	(X)	(X)	(X)	
For Ivabradine RCT participants only										
Enroll to RCT/Randomize			X	X			X			
Ivabradine or placebo treatment***			-----							
Echocardiogram			X						X	
Dose Adjustments				X	X	X	X	X	X	
Unblinded DSMB assessment							X			
Rich PK/PD assessment							X**			

Ivabradine Levels			X	X	X	X	X	X	X
--------------------------	--	--	---	---	---	---	---	---	---

(X) – performed only for those enrolled in the RCT

* - Performed only for a subset of individuals

** - Performed only for those individuals randomized to placebo

*** - All volunteers in the RCT will receive ivabradine following the Data Safety Monitoring Board assessment at month 3

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.25.23289110>; this version posted April 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
